Crinetics Pharmaceuticals Inc Stock News

ValuEngine downgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports. Several other research analysts have also

These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.

SAN DIEGO, Feb. 19, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

Analysts expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to announce $300,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Crinetic

BidaskClub downgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a strong-buy rating to a buy rating in a research report released on Saturday morning, BidAskClub reports. A number of othe

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) major shareholder Vivo Capital Viii, Llc sold 13,920 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average pri

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) major shareholder Vivo Capital Viii, Llc sold 5,400 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The st

While not a mind-blowing move, it is good to see that the Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) share price...

Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According

Several brokerages have updated their recommendations and price targets on shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) in the last few weeks: 1/22/2020 – Crinetics Pharmaceuticals was upgrade

ValuEngine downgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a buy rating to a hold rating in a research note released on Friday morning, ValuEngine reports. CRNX has been the topic of

TheStreet upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a d rating to a c- rating in a research report released on Thursday, TheStreetRatingsTable reports. CRNX has been the subject

SAN DIEGO, Jan. 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.

How do we determine whether Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world,

SAN DIEGO, Nov. 26, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.